2.58

0.39% -0.010

C 4 Therapeutics Inc (CCCC)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$2.59

Offen:

$2.61

24-Stunden-Volumen:

1.01M

Relative Volume:

0.50

Marktkapitalisierung:

$250.04M

Einnahmen:

$20.76M

Nettoeinkommen (Verlust:

$-132.49M

KGV:

-0.9663

EPS:

-2.67

Netto-Cashflow:

$-108.55M

1W Leistung:

-8.19%

1M Leistung:

+10.26%

6M Leistung:

+64.33%

1J Leistung:

-40.14%

1-Tages-Spanne:

$2.50

$2.61

1-Wochen-Bereich:

$2.49

$2.76

52-Wochen-Spanne:

$1.085

$4.885

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Firmenname

C 4 Therapeutics Inc

Sektor

Healthcare (1124)

Branche

Biotechnology (627)

Telefon

(617) 231-0700

Adresse

490 ARSENAL WAY, WATERTOWN

Mitarbeiter

110

Twitter

Nächster Verdiensttermin

2025-02-24

Neueste SEC-Einreichungen

CCCC's Discussions on Twitter

Vergleichen Sie CCCC mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CCCC C 4 Therapeutics Inc	2.58	251.01M	20.76M	-132.49M	-108.55M	-2.67
VRTX Vertex Pharmaceuticals Inc	444.64	110.88B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	726.21	72.79B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	890.11	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	404.46	54.85B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	189.85	41.41B	447.02M	-1.18B	-906.14M	-6.1812

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-02	Eingeleitet	TD Cowen	Buy
2025-09-17	Eingeleitet	Barclays	Overweight
2025-09-15	Hochstufung	Stephens	Equal-Weight → Overweight
2025-09-04	Eingeleitet	Guggenheim	Buy
2024-12-19	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-11-18	Eingeleitet	Stephens	Equal-Weight
2024-01-29	Hochstufung	JP Morgan	Underweight → Neutral
2023-12-13	Hochstufung	Stifel	Hold → Buy
2023-02-24	Hochstufung	Credit Suisse	Underperform → Neutral
2023-02-24	Herabstufung	JP Morgan	Neutral → Underweight
2022-11-04	Herabstufung	JP Morgan	Overweight → Neutral
2022-10-11	Eingeleitet	Morgan Stanley	Underweight
2022-04-28	Eingeleitet	Credit Suisse	Underperform
2022-04-11	Herabstufung	BofA Securities	Buy → Neutral
2022-03-10	Eingeleitet	JP Morgan	Overweight
2022-02-11	Fortgesetzt	BMO Capital Markets	Outperform
2022-02-10	Eingeleitet	Wells Fargo	Equal Weight
2021-11-23	Eingeleitet	BofA Securities	Buy
2021-10-14	Eingeleitet	SVB Leerink	Mkt Perform
2021-09-30	Eingeleitet	Stifel	Hold
2021-06-04	Eingeleitet	H.C. Wainwright	Buy
2021-03-31	Eingeleitet	BMO Capital Markets	Outperform
2020-10-28	Eingeleitet	UBS	Buy
2020-10-27	Eingeleitet	BMO Capital Markets	Outperform
2020-10-27	Eingeleitet	Jefferies	Buy

Alle ansehen

C 4 Therapeutics Inc Aktie (CCCC) Neueste Nachrichten

Dec 10, 2025

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Dec 10, 2025

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Dec 10, 2025

Dec 08, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Dec 08, 2025

Dec 06, 2025

Hedge Fund Moves: Will C4 Therapeutics Inc stock remain a Wall Street favorite2025 Risk Factors & Free Expert Verified Stock Movement Alerts - BỘ NỘI VỤ

Dec 06, 2025

Dec 05, 2025

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Dec 05, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 05, 2025

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Dec 05, 2025

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Dec 05, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - pharmiweb.com

Dec 05, 2025

Dec 04, 2025

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Dec 04, 2025

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 04, 2025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Dec 04, 2025

Dec 03, 2025

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance

Dec 03, 2025

TD Cowen Begins Coverage on C4 Therapeutics (NASDAQ:CCCC) - MarketBeat

Dec 03, 2025

Dec 02, 2025

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Dec 02, 2025

This Cloudflare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Dec 02, 2025

TD Cowen Initiates Coverage of C4 Therapeutics (CCCC) with Buy Recommendation - Nasdaq

Dec 02, 2025

Dec 01, 2025

PTC Therapeutics (NASDAQ: PTCT) approves 2,000 options, 8,200 RSUs as inducement grants - Stock Titan

Dec 01, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 01, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm

Dec 01, 2025

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Dec 01, 2025

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (2025-12-01) - Seeking Alpha

Dec 01, 2025

Nov 28, 2025

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record

Nov 28, 2025

Nov 26, 2025

C4 Therapeutics Reports Q3 2025 Financial Results - MSN

Nov 26, 2025

Mineralys Therapeutics reports inducement award under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Nov 26, 2025

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 26, 2025

Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss - Seeking Alpha

Nov 26, 2025

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com

Nov 26, 2025

Nov 25, 2025

C4 Therapeutics files $400M mixed shelf offering - MSN

Nov 25, 2025

CCCC SEC FilingsC4 Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Nov 25, 2025

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference - The Manila Times

Nov 25, 2025

C4 Therapeutics (NASDAQ: CCCC) fireside chat at Evercore conference Dec. 3 2025 - Stock Titan

Nov 25, 2025

Nov 21, 2025

C4 Therapeutics Inc files for mixed shelf of up to $400 millionSEC filing - marketscreener.com

Nov 21, 2025

[S-3] C4 Therapeutics, Inc. Shelf Registration Statement | CCCC SEC FilingForm S-3 - Stock Titan

Nov 21, 2025

Nov 20, 2025

How C4 Therapeutics Inc. stock responds to policy changes2025 Support & Resistance & Growth Focused Investment Plans - newser.com

Nov 20, 2025

Nov 19, 2025

Using economic indicators to assess C4 Therapeutics Inc. potentialWall Street Watch & Accurate Entry/Exit Alerts - newser.com

Nov 19, 2025

Wells Fargo Upgrades C4 Therapeutics (CCCC) - MSN

Nov 19, 2025

C4 Therapeutics Inc. stock trend forecastJuly 2025 Selloffs & Detailed Earnings Play Strategies - newser.com

Nov 19, 2025

Nov 18, 2025

Stoke Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Nov 18, 2025

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Yahoo Finance

Nov 18, 2025

Nov 17, 2025

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 17, 2025

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Nov 17, 2025

Nov 16, 2025